STAY UP TO DATE

Press Releases

Latest press release

17 September 2024

MinervaX scaling up supply of novel GBS vaccine, ahead of phase III studies Wacker Biotech to manufacture active vaccine protein ingredients and prepare for commercial supply after regulatory approval Vaccine to address the unmet medical burden of GBS, both by maternal vaccination to prevent adverse pregnancy outcomes and life-threatening infections in infants and by vaccination…

Previous press releases

11 October 2023

New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company’s efforts to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus Copenhagen, Denmark, 11 October 2023 – MinervaX ApS,…

27 June 2023

Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated in Q4, 2023 Copenhagen, Denmark, 27 June 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has…

17 April 2023

Expands development of novel GBS vaccine in older adult population Targeting significant and growing unmet medical need of GBS infection Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its…